143 related articles for article (PubMed ID: 36938826)
21. Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research.
Alqaisi A; Chen L; Romond E; Chambers M; Stevens M; Pasley G; Awasthi M; Massarweh S
Breast Cancer Res Treat; 2014 Nov; 148(2):437-44. PubMed ID: 25257728
[TBL] [Abstract][Full Text] [Related]
22. The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer.
El Ansari R; Alfarsi L; Craze ML; Masisi BK; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2020 May; 181(1):1-12. PubMed ID: 32200487
[TBL] [Abstract][Full Text] [Related]
23. Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials.
van Mackelenbergh MT; Denkert C; Nekljudova V; Karn T; Schem C; Marmé F; Stickeler E; Jackisch C; Hanusch C; Huober J; Fasching PA; Blohmer JU; Kümmel S; Müller V; Schneeweiss A; Untch M; von Minckwitz G; Weber KE; Loibl S
Breast Cancer Res Treat; 2018 Jan; 167(1):59-71. PubMed ID: 28875243
[TBL] [Abstract][Full Text] [Related]
24. Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer.
Chen M; Wu J; Liu D; Chen W; Lin C; Andriani L; Ding S; Huang O; He J; Chen X; Chen W; Li Y; Shen K; Zhu L
Clin Breast Cancer; 2022 Feb; 22(2):e147-e156. PubMed ID: 34244052
[TBL] [Abstract][Full Text] [Related]
25. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
[TBL] [Abstract][Full Text] [Related]
26. Effects of tumor-specific CAP1 expression and body constitution on clinical outcomes in patients with early breast cancer.
Bergqvist M; Elebro K; Sandsveden M; Borgquist S; Rosendahl AH
Breast Cancer Res; 2020 Jun; 22(1):67. PubMed ID: 32560703
[TBL] [Abstract][Full Text] [Related]
27. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
28. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.
Frogne T; Laenkholm AV; Lyng MB; Henriksen KL; Lykkesfeldt AE
Breast Cancer Res; 2009; 11(1):R11. PubMed ID: 19239686
[TBL] [Abstract][Full Text] [Related]
29. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
30. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
[TBL] [Abstract][Full Text] [Related]
31. Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients.
Dodson A; Parry S; Ibrahim M; Bartlett JM; Pinder S; Dowsett M; Miller K
J Pathol Clin Res; 2018 Oct; 4(4):262-273. PubMed ID: 30066480
[TBL] [Abstract][Full Text] [Related]
32. ETS transcription factor ESE-1/Elf3 is an independent prognostic factor of survival in HR
Kar A; Koto K; Walker D; Trudeau T; Edgerton S; Thor A; Gutierrez-Hartmann A
Breast Cancer Res Treat; 2020 Aug; 182(3):601-612. PubMed ID: 32562116
[TBL] [Abstract][Full Text] [Related]
33.
Uzelac B; Krivokuca A; Susnjar S; Milovanovic Z; Supic G
Genet Test Mol Biomarkers; 2021 Mar; 25(3):227-235. PubMed ID: 33734898
[No Abstract] [Full Text] [Related]
34. Prognostic significance of young age (<35 years) by subtype based on ER, PR, and HER2 status in breast cancer: a nationwide registry-based study.
Kim EK; Noh WC; Han W; Noh DY
World J Surg; 2011 Jun; 35(6):1244-53. PubMed ID: 21472372
[TBL] [Abstract][Full Text] [Related]
35. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study.
Li X; Zhang X; Liu J; Shen Y
BMC Cancer; 2020 Nov; 20(1):1102. PubMed ID: 33187507
[TBL] [Abstract][Full Text] [Related]
36. Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?
Albergaria A; Ricardo S; Milanezi F; Carneiro V; Amendoeira I; Vieira D; Cameselle-Teijeiro J; Schmitt F
BMC Cancer; 2011 Jul; 11():299. PubMed ID: 21762477
[TBL] [Abstract][Full Text] [Related]
37. Combined analysis of receptor expression reflects inter-and intra-tumor heterogeneity in HR+/HER2+ breast cancer.
Ju J; Du F; Gao SL; Si YR; Hu NL; Liu DX; Wang X; Yue J; Zheng FC; Kang YK; Yang ZX; Ma F; Xu BH; Yuan P
Breast Cancer Res Treat; 2022 Jul; 194(2):221-230. PubMed ID: 35699854
[TBL] [Abstract][Full Text] [Related]
38. The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study.
Han Y; Wu Y; Xu H; Wang J; Xu B
Int J Clin Oncol; 2022 Apr; 27(4):707-716. PubMed ID: 35041101
[TBL] [Abstract][Full Text] [Related]
39. The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial.
Linardou H; Kalogeras KT; Kronenwett R; Kouvatseas G; Wirtz RM; Zagouri F; Gogas H; Christodoulou C; Koutras AK; Samantas E; Pectasides D; Bafaloukos D; Fountzilas G
Breast Cancer Res; 2012 Nov; 14(6):R145. PubMed ID: 23146280
[TBL] [Abstract][Full Text] [Related]
40. Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
Linardou H; Kalogeras KT; Kronenwett R; Alexopoulou Z; Wirtz RM; Zagouri F; Scopa CD; Gogas H; Petraki K; Christodoulou C; Pavlakis K; Koutras AK; Samantas E; Patsea H; Pectasides D; Bafaloukos D; Fountzilas G
Anticancer Res; 2015 Jul; 35(7):4023-36. PubMed ID: 26124351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
